Special Issue

Recent Advances on the Role of Intensity–Modulated Radiotherapy in Cancer

Message from the Guest Editor

The emergence of intensity-modulated radiotherapy (IMRT) was one of the most revolutionary events in radiation oncology in the past 20 years. It enables the optimization of doses to tumors and the sparing of normal organs with information technology.In this IMRT era, new research fields such as hypofractionation, reirradiation, and palliative stereotactic radiotherapy have been developed. Information technology, artificial intelligence, and quality control/assurance came to be the main issues in this era.

Recently, proton therapy (PT) has emerged as the next generation following IMRT. PT has a physical characteristic known as the Bragg peak, where protons deposit most of their energy over a finite range without exit dose. Despite the edge, the optimal role of PT is not as well-defined as IMRT for now. It is partially caused by the lack of enough clinical evidence that PT is superior to IMRT. If you forecast the future, IMRT may be still the main tool for most radiation oncologists in the next decade.

In this Special Issue, we aim to elucidate the role of IMRT by reviewing the literature and reporting new findings addressing some of the unanswered questions.

Guest Editor

Dr. Taro Murai

Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Deadline for manuscript submissions

31 August 2025

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/187020

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)